{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-229714","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-05-19T12:07:26+00:00","discovered_at":"2026-05-19T12:10:00.331172+00:00","generated_at":"2026-05-19T12:10:18.157842+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Artiva CFO departs; CEO assumes financial duties; Miralles becomes President","bullets":["CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.","CEO Fred Aslan becomes principal financial and accounting officer after stepping down as President.","Diego Miralles resigns from board, appointed President and Head of R&D; $600k salary, 45% bonus target.","Miralles awarded inducement equity: 232,500 options and 77,500 RSUs under 2025 Inducement Plan.","Board size reduced from 8 to 7; Miralles's consulting agreement ended May 17."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-229714","json":"https://secwatch.observer/filing/0001193125-26-229714.json","markdown":"https://secwatch.observer/filing/0001193125-26-229714.md","text":"https://secwatch.observer/filing/0001193125-26-229714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/artv-20260518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:10:18.157842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1303a4c8bd","claim":"Diego Miralles resigned as Director at Artiva Biotherapeutics, Inc..","evidence_excerpt":"On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d2c6fe7565","claim":"Fred Aslan was appointed as principal financial officer and principal accounting officer at Artiva Biotherapeutics, Inc..","evidence_excerpt":"On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"fc45f2676a","claim":"Thad Huston departed as Chief Financial Officer at Artiva Biotherapeutics, Inc..","evidence_excerpt":"On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}